Project Grant R01HL179626

Award Date 5/15/25
Completion Date 3/31/29
Dollars Obligated $740K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) is funding research to define the roles of platelets and macrophages in the healing of abdominal aortic aneurysms (AAA). The $445,500 award, with a performance period from August 2024 to July 2026, will be used by the University of Cincinnati to study how platelet-leukocyte interactions and cross-talk can support regenerative tissue repair and healing of cardiovascular damage...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports research under the Cardiovascular Diseases Research program (CFDA 93.837). The $169,560 grant awarded to the Regents of the University of Michigan aims to investigate the role of the PERK/EIF2A/ATF4 endoplasmic reticulum stress response and MLL1-mediated regulation of CHOP gene expression in vascular smooth muscle cell (VSMC) apoptosis and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $287,000 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to investigate the use of photodynamic therapy (PDT) for treating abdominal aortic aneurysms (AAA). The project aims to evaluate how PDT can enhance extracellular matrix cross-linking and eliminate proliferating immune cells within the aortic wall to halt AAA growth. Specifically, the research...
This $122,625 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify small molecule compounds that can activate the SIRT1 protein and thereby inhibit the progression of aortic aneurysms in Marfan syndrome patients. The key research activities include in silico screening of a molecular library to identify promising SIRT1 activating compounds, followed by in vitro testing of these...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,508,095 to Yale University to conduct research on the underlying mechanisms of thoracic aortic disease. The overarching goal is to elucidate how aberrant interactions between vascular cells and the extracellular matrix lead to the progressive deterioration of the thoracic aorta, potentially resulting in aortic dilatation, dissection,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $817,498 in funding to Trustees of Boston University (Boston University Medical Campus) to conduct research on the role of thiol redox signaling in aortic aneurysm development, with a focus on Marfan syndrome. The research aims to investigate how oxidative inactivation of the SIRT1 protein, through glutathionylation, contributes to vascular smooth muscle...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $528,179 to the University of Miami to investigate methods for improving neovascularization in peripheral arterial disease (PAD) and critical limb ischemia (CLI). The key research objectives are to: 1) determine if extracellular vesicles mediate the systemic reprogramming of bone marrow-derived monocytes during ischemia training; 2) examine...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $705,944 to Yale University to conduct research on the mechanisms underlying thoracic aortopathy, which is a leading cause of morbidity and mortality. The research aims to elucidate the molecular, cellular, and biomechanical factors that drive the development and progression of aortic aneurysms, dissections, and ruptures,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,508,741 to investigate the functional interactions between lipoproteins and protease inhibitors in atherosclerosis. The research aims to: 1) examine the structural and functional interactions between lipoproteins, such as LDL and HDL, and the protease inhibitor alpha-1-antitrypsin (AAT); 2) determine the role of...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $723,084 to the University of Colorado-Denver to investigate the role of the PAR1/IL-17 signaling axis in the development and progression of chronic thromboembolic pulmonary hypertension (CTEPH). The research aims to determine how this signaling pathway contributes to abnormal cellular phenotypes in chronic thrombus, the initiation and progression of CTEPH,...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $740,338 to the University of Cincinnati to study the role of Protease Activated Receptor 2 (PAR2) in the initiation and progression of abdominal aortic aneurysm (AAA). The research aims to determine the effect of VSMC-specific PAR2 deletion and PAR2 inhibition in mouse models of aneurysmal disease, as well as delineate how PAR2 mediates CD34+ progenitor cells and their impact on AAA initiation and progression. Completion of these research objectives is expected to advance the understanding of PAR2 and associated pathways in AAA, potentially leading to new pharmaceutical interventions for this condition where limited treatment options currently exist. The project period runs from May 15, 2025 to March 31, 2029.

Generated 6/17/25, 3:48 AM